Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H30N4O2 |
Molar mass | 370.497 g·mol−1 |
3D model (JSmol) | |
| |
|
ADB-CHMINACA (also known as ADMB-CHMINACA[3] and MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication.[4][5] It was identified in cannabinoid blends in Japan in early 2015.[6]